SOURCE: StockCall


July 01, 2011 09:07 ET

Equity Research on Immucor Inc. and Celldex Therapeutics Inc. - New Drugs in the Pipeline Bring Positive Outlook

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jul 1, 2011) - offers investors comprehensive research on the Diagnostic Substances industry and has completed analytical research on Immucor Inc. (NASDAQ: BLUD) and Celldex Therapeutics Inc. (NASDAQ: CLDX). Register with us today at to have free access to these researches.

Many companies in the Healthcare Diagnostic Substances sector have seen limited growth over the past year. With new breakthroughs in the field of cancer research and treatment drugs though, these businesses could be in for a much needed boost. Register now at to have free access to our reports on the Diagnostic Substances industry. is an online platform where investors doing their due-diligence on the Diagnostic Substances industry can have easy and free access to our analyst research and opinions on Immucor Inc. and Celldex Therapeutics Inc.; investors and shareholders of these companies can simply register for a complimentary membership at

Companies like Celldex Therapeudics Inc. may see an increase in their value as some new cancer treating drugs are nearing phase 3 FDA trials. When drugs make it through this final phase of testing, they are approved and ready to go to market. Celldex Therapeutics Inc. research report is available for free by signing up now at

As Immunotherapy drugs are also starting to get approval from the FDA, companies providing these treatments may benefit from a rising trend. Most immunotherapies have an advantage over oral cancer drugs in that they can attack cancer cells without damaging the healthy cells around them. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Companies like Immucor Inc. that identify properties of human blood for transfusion are also in demand, and competition between the companies that provide these diagnostics should remain strong. Immucor Inc. research report is accessible for free by registering today at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information